

## URODYNAMIC FINDINGS IN TRANSURETHRAL RESECTION OF THE PROSTATE FOR PATIENTS WHO FAILED DRUG THERAPY

### Hypothesis / aims of study

The drug treatment is widely used in benign prostate hyperplasia(BPH). But some patients continuously appeal for lower urinary tract symptoms (LUTS) so they want to surgical treatment. The aim of this study was to investigate urodynamic findings in transurethral resection of the prostate (TURP) for patients who failed drug therapy.

### Study design, materials and methods

A retrospective study was conducted in 100 patients with TURP of prostate volume less than 50cc. Group 1 (n=21) was treated only alpha blocker at least 3 months, group 2 (n=26) was treated alpha blocker and 5-alpha reductase inhibitor at least 6 months, and group 3 (n=53) was not treated with drug before TURP. They underwent preoperative urodynamic studies, the International Prostate Symptom Score (IPSS)/quality of life (QoL), maximal flow rate (Qmax), post-voiding residual urine volume, transrectal ultrasonography, and serum prostate-specific antigen (PSA) measurement.

### Results

The mean Abrams-Griffiths number of each group were 41.2±21.5 (group 1), 40.8±18.8 (group 2), 42.6±22.6 (group 3), respectively (p=0.851). The mean prostate volume and PSA were 29.7±5.6cc, 32.0±9.4cc, 35.9±9.1cc (p=0.034) and 2.1±1.8ng/ml, 2.4±2.1ng/ml, 2.9±2.7ng/ml (p=0.751), respectively. The Qmax and IPSS were 10.1±3.7ml/s, 9.8±4.6ml/s, 9.0±4.2ml/s (p=0.512) and 22.5±5.9, 15.8±7.2, 21.4±6.8 (p=0.016), respectively.

### Interpretation of results

The drug therapy is effective treatment of BPH. But some patients complain lower urinary tract symptoms during drug treatment. On the result of urodynamic study, they have bladder outlet obstruction.

### Concluding message

If the patients complained of LUTS during drug treatment, they should be re-evaluate of LUTS and required aggressive treatment.

Table 1. Patient's characteristics between three groups.

	Group 1	Group 2	Group 3	p value
Age(years)	66.5±8.5	69.1±9.3	69.8±9.8	0.251
Prostate volume(g)	29.7±5.6	32.0±9.4	35.9±9.1	0.034
Adenoma(g)	12.0±4.1	14.9±7.8	16.2±8.2	0.174
PSA(ng/ml)	2.1±1.8	2.4±2.1	2.9±2.7	0.751
IPSS	22.5±5.9	15.8±7.2	21.4±6.8	0.016
QoL	4.6±1.0	3.5±1.3	4.3±1.2	0.053
Qmax(ml/s)	10.1±3.7	9.8±4.6	9.0±4.2	0.512
Voided volume(ml)	208.8±144.1	229.3±146.8	175.1±118.6	0.457
AG number	41.2±21.5	40.8±18.8	42.6±22.6	0.851

### Disclosures

**Funding:** None **Clinical Trial:** No **Subjects:** HUMAN **Ethics Committee:** Eulji Hospital Institutional Review Board **Helsinki:** Yes **Informed Consent:** Yes